Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
Copenhagen Post2h
Novo shares take another hit after new weight loss figures revealed
The Novo Nordisk drug Wegovy has produced a weight loss of 20.7 percent in a study where the company tested a higher dose, the company wrote in a press release on Friday.In comparison, a dose of the ...
Novo Nordisk: Excellent Opportunity To Buy The Dip
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...
Novo Nordisk A/S - share repurchase programme
On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No ...
devdiscourse1d
Denmark's Diplomatic Push: Navigating Greenland Tensions
Denmark's Prime Minister Mette Frederiksen initiated discussions with business leaders in response to U.S. President-elect ...
Trump’s quest for Greenland could make Ozempic even more expensive
President-elect Donald Trump’s quest to buy Greenland from Denmark could make Ozempic and Wegovy, the weight-loss and diabetes drugs exploding in popularity, even more expensive for Americans.
Novo Nordisk (0QIU) Receives a Hold from Bernstein
In a report released today, Florent Cespedes from Bernstein maintained a Hold rating on Novo Nordisk (0QIU – Research Report), with a price ...
Jim Cramer on Novo Nordisk A/S (NVO): ‘That’s Denmark’s Jugular’
We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...